Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

iRAPID: Infliximab Infusion Rate in Pediatric Inflammatory Bowel Disease. A Randomized Non-inferiority Trial of Infusion Reactions With Infliximab Infusion-rates of 30 Minutes and 60 Minutes

NCT06839820 is registered in ClinicalTrials.gov with University Hospital, Akershus as lead sponsor.

NCT NCT06839820
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06839820 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
iRAPID: Infliximab Infusion Rate in Pediatric Inflammatory Bowel Disease. A Randomized Non-inferiority Trial of Infusion Reactions With Infliximab Infusion-rates of 30 Minutes and 60 Minutes
Lead sponsor
University Hospital, Akershus
Phase
Not applicable
Overall status
Active, not recruiting
Start date
February 1, 2025
Completion date
December 31, 2026
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ibd (inflammatory bowel disease), infliximab, infusion, patient satisfaction